IL231107A - An aryl-hydrocarbon receptor inhibitor (AHR) for the treatment and / or prevention of quinoranine-dependent cancer - Google Patents
An aryl-hydrocarbon receptor inhibitor (AHR) for the treatment and / or prevention of quinoranine-dependent cancerInfo
- Publication number
- IL231107A IL231107A IL231107A IL23110714A IL231107A IL 231107 A IL231107 A IL 231107A IL 231107 A IL231107 A IL 231107A IL 23110714 A IL23110714 A IL 23110714A IL 231107 A IL231107 A IL 231107A
- Authority
- IL
- Israel
- Prior art keywords
- kynurenine
- ahr
- inhibitor
- aryl
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
- C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
- C12Y113/11011—Tryptophan 2,3-dioxygenase (1.13.11.11), i.e. indolamine 2,3-dioxygenase 2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
- C12Y113/11017—Indole 2,3-dioxygenase (1.13.11.17)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161531861P | 2011-09-07 | 2011-09-07 | |
| PCT/EP2012/067504 WO2013034685A1 (en) | 2011-09-07 | 2012-09-07 | Means and methods for treating and/or preventing natural ahr ligand-dependent cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL231107A0 IL231107A0 (en) | 2014-04-30 |
| IL231107A true IL231107A (en) | 2017-11-30 |
Family
ID=46832380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL231107A IL231107A (en) | 2011-09-07 | 2014-02-24 | An aryl-hydrocarbon receptor inhibitor (AHR) for the treatment and / or prevention of quinoranine-dependent cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9593062B2 (enExample) |
| EP (1) | EP2753315B1 (enExample) |
| JP (1) | JP6047160B2 (enExample) |
| KR (1) | KR20140074330A (enExample) |
| CN (1) | CN104023713A (enExample) |
| AU (1) | AU2012306285B2 (enExample) |
| BR (1) | BR112014004937A2 (enExample) |
| CA (1) | CA2846275C (enExample) |
| ES (1) | ES2626015T3 (enExample) |
| HK (1) | HK1201471A1 (enExample) |
| IL (1) | IL231107A (enExample) |
| MX (1) | MX348941B (enExample) |
| RU (1) | RU2640913C2 (enExample) |
| WO (1) | WO2013034685A1 (enExample) |
| ZA (1) | ZA201401011B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2953065B2 (ja) | 1990-12-28 | 1999-09-27 | 石川島播磨重工業株式会社 | 宇宙飛翔体 |
| CA3173052A1 (en) | 2013-08-30 | 2015-03-05 | Board Of Regents, The University Of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| IL250833B (en) | 2014-08-29 | 2022-09-01 | Univ Texas | Administration of kynurenine depleting enzymes for tumor therapy |
| EP3274053A4 (en) | 2015-03-23 | 2018-12-05 | The Brigham and Women's Hospital, Inc. | Tolerogenic nanoparticles for treating diabetes mellitus |
| PT3370768T (pt) | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| EP3423483B1 (en) | 2016-03-02 | 2025-09-24 | Board Of Regents Of the University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| CN107510694B (zh) * | 2016-06-16 | 2022-03-29 | 中国科学院上海巴斯德研究所 | 激活潜伏感染的艾滋病病毒的化合物及其在艾滋病治疗中的应用 |
| CN106214673A (zh) * | 2016-08-31 | 2016-12-14 | 深圳市第二人民医院 | 表没食子儿茶素没食子酸酯在制备预防或治疗膀胱肿瘤的药物中的用途 |
| WO2018085775A1 (en) * | 2016-11-04 | 2018-05-11 | Ohio State Innovation Foundation | Methods and compositions for treating multiple myeloma and increasing antibody dependent cell cytotoxicity by targeting the aryl hydrocarbon receptor |
| CN111163766A (zh) | 2017-08-17 | 2020-05-15 | 医肯纳肿瘤学公司 | Ahr抑制剂和其用途 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CA3096549A1 (en) | 2018-04-16 | 2019-10-24 | Board Of Regents, The University Of Texas System | Human kynureninase enzymes and uses thereof |
| RU2699932C1 (ru) * | 2018-11-14 | 2019-09-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ прогнозирования риска развития рака печени у экспериментальных животных |
| CN109813913B (zh) * | 2019-01-31 | 2021-11-09 | 中国医学科学院肿瘤医院 | 芳烃受体(AhR)在预测免疫治疗效果中的应用 |
| CN114828863A (zh) | 2019-10-17 | 2022-07-29 | 医肯纳肿瘤学公司 | 聚乙二醇化犬尿氨酸酶以及其用于治疗癌症的用途 |
| BR112022013673A2 (pt) * | 2020-01-10 | 2022-09-13 | Ikena Oncology Inc | Inibidores de ahr e seus usos |
| CN114019164B (zh) * | 2020-12-31 | 2023-11-21 | 中国科学院生态环境研究中心 | 筛选抗胶质瘤药物的方法和试剂盒 |
| CN112807305A (zh) * | 2020-12-31 | 2021-05-18 | 中国科学院生态环境研究中心 | Ch223191在抑制肿瘤细胞迁移中的应用 |
| CN114470238A (zh) * | 2022-03-25 | 2022-05-13 | 华中科技大学同济医学院附属协和医院 | AhR抑制剂CH223191在制备抑制肿瘤相关巨噬细胞药物中的应用 |
| CN121378137A (zh) * | 2025-11-05 | 2026-01-23 | 青岛大学 | 一种芳香烃受体ahr抑制剂ch223191的合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| JP4587652B2 (ja) | 2002-09-09 | 2010-11-24 | 株式会社フラバミン | 新規フラボノイド化合物及びその利用 |
| KR20050095859A (ko) * | 2003-02-04 | 2005-10-04 | 가부시키가이샤 야쿠루트 혼샤 | 유방암 내성 단백 저해제 |
| EP2023910B1 (en) * | 2006-05-03 | 2013-06-19 | Symrise AG | Ah receptor antagonists |
| WO2010008427A1 (en) | 2008-04-11 | 2010-01-21 | Ludwig Institute For Cancer Research Ltd. | Tryptophan catabolism in cancer treatment and diagnosis |
| PE20100362A1 (es) * | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
-
2012
- 2012-09-07 HK HK15102080.0A patent/HK1201471A1/xx unknown
- 2012-09-07 AU AU2012306285A patent/AU2012306285B2/en active Active
- 2012-09-07 BR BR112014004937A patent/BR112014004937A2/pt not_active Application Discontinuation
- 2012-09-07 EP EP12758452.2A patent/EP2753315B1/en active Active
- 2012-09-07 WO PCT/EP2012/067504 patent/WO2013034685A1/en not_active Ceased
- 2012-09-07 ES ES12758452.2T patent/ES2626015T3/es active Active
- 2012-09-07 CN CN201280043522.9A patent/CN104023713A/zh active Pending
- 2012-09-07 JP JP2014528990A patent/JP6047160B2/ja active Active
- 2012-09-07 CA CA2846275A patent/CA2846275C/en active Active
- 2012-09-07 RU RU2014104696A patent/RU2640913C2/ru active
- 2012-09-07 MX MX2014002776A patent/MX348941B/es active IP Right Grant
- 2012-09-07 KR KR1020147009041A patent/KR20140074330A/ko not_active Ceased
- 2012-09-07 US US14/343,350 patent/US9593062B2/en active Active
-
2014
- 2014-02-10 ZA ZA2014/01011A patent/ZA201401011B/en unknown
- 2014-02-24 IL IL231107A patent/IL231107A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MX348941B (es) | 2017-07-04 |
| US9593062B2 (en) | 2017-03-14 |
| BR112014004937A2 (pt) | 2017-06-20 |
| ZA201401011B (en) | 2018-07-25 |
| CN104023713A (zh) | 2014-09-03 |
| ES2626015T3 (es) | 2017-07-21 |
| CA2846275A1 (en) | 2013-03-14 |
| JP6047160B2 (ja) | 2016-12-21 |
| HK1201471A1 (en) | 2015-09-04 |
| EP2753315B1 (en) | 2017-03-01 |
| RU2014104696A (ru) | 2015-10-20 |
| MX2014002776A (es) | 2014-11-25 |
| WO2013034685A1 (en) | 2013-03-14 |
| AU2012306285A1 (en) | 2014-02-27 |
| JP2014526450A (ja) | 2014-10-06 |
| EP2753315A1 (en) | 2014-07-16 |
| IL231107A0 (en) | 2014-04-30 |
| AU2012306285B2 (en) | 2017-05-18 |
| US20140294860A1 (en) | 2014-10-02 |
| RU2640913C2 (ru) | 2018-01-12 |
| CA2846275C (en) | 2019-07-16 |
| KR20140074330A (ko) | 2014-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL232128B (en) | Tor kinase inhibitors for cancer treatment | |
| IL227429A0 (en) | The components and methods of cancer treatment | |
| EP2768443A4 (en) | METHODS AND DEVICES FOR TREATING HYPERTENSION | |
| AP3269A (en) | Methods and compounds for treating paramyxoviridaevirus infections | |
| IL223201A (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| IL231107A0 (en) | Means and methods for the treatment and/or prevention of cancer dependent on a natural ligand for ahr | |
| IL218987A0 (en) | Methods and compositions for treating cancer | |
| PL2434891T3 (pl) | Sposoby leczenia nowotworu złośliwego i stanów nienowotworowych | |
| EP2504028A4 (en) | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 | |
| ZA201205004B (en) | Methods for treating pancreatic cancer | |
| SG10201500124VA (en) | Methods and Compositions for Treating Cancer | |
| IL232530B (en) | A combination of factors for cancer treatment | |
| PL2858647T3 (pl) | Inhibitory receptora h4 do leczenia szumów usznych | |
| SG10201502566SA (en) | Use of novel pan-cdk inhibitors for treating tumors | |
| IL229231A0 (en) | Preparations and methods for the treatment of cancer | |
| SG11201400976WA (en) | Methods and pharmaceutical compositions for treating cancer | |
| GB201012845D0 (en) | Inhibition of dicer function for treatment of cancer | |
| PL2817286T3 (pl) | Inhibitory kinazy do leczenia raka | |
| ZA201407551B (en) | Methods of treating cancer using aurora kinase inhibitors | |
| IL225520A0 (en) | History of 4-(methylaminophenoxy)pyridin-3-yl-benzamide for cancer treatment | |
| ZA201202379B (en) | Antagonists of dsgs2 for treatment of cancer | |
| LT2519231T (lt) | Proteosomų inhibitoriai vėžio gydymui | |
| EP2560648A4 (en) | METHOD OF TREATING PANCREATIC CANCER | |
| EP2593100A4 (en) | METHOD OF TREATING REFRACTORY CANCER | |
| AP2011005893A0 (en) | Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |